Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Post by MetzGERon Apr 26, 2020 6:38am

243 Views

Post# 30954330

Inv3strr comment

@Inv3strr i appreciated your positive thoughts on Replicel the last time. You said that when RCH-01 results of SHISEIDO are published the stock price of Replicel will go high and that SHISEIDO would buy Replicel company.

now we have a lot of clear points:
- published RCH-01 data
- no movement in dermal injector since 5 months
- no movement of YOFOTO

I would like to hear your thoughts on that. Thank you

Bullboard Posts

A junior copper-gold stock trading at a bargain of monumental proportions